WASHINGTON (Reuters) – The U.S. Supreme Court on Monday declined to take up Amgen Inc’s bid to reinstate a jury verdict it won against rivals Regeneron Pharmaceuticals Incand Sanofi SAin patent dispute over cholesterol medication.
The justices turned away Amgen’s appeal of a 2017 decision by a lower court to set aside a jury’s verdict that two Amgen patents were valid and nullify a ban on sales of Regeneron and Sanofi SA’s cholesterol-lowering drug Praluent.
Amgen - US - Court
Amgen had argued that the U.S. Court of...
Wake Up To Breaking News!
Millions in tribute, but not a penny left for charity.